购物车
- 全部删除
- 您的购物车当前为空
SRI 31215 TFA 是 matriptase、hepsin、肝细胞生长因子激活剂(HGFA)的三重抑制剂,IC50值分别为 0.69 μM、0.65 μM、0.3 μM。它能够阻断 pro-HGF 的活化,模拟 HAI-1/2 的活性。
为众多的药物研发团队赋能,
让新药发现更简单!
SRI 31215 TFA 是 matriptase、hepsin、肝细胞生长因子激活剂(HGFA)的三重抑制剂,IC50值分别为 0.69 μM、0.65 μM、0.3 μM。它能够阻断 pro-HGF 的活化,模拟 HAI-1/2 的活性。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 358 | 现货 | |
5 mg | ¥ 893 | 现货 | |
10 mg | ¥ 1,390 | 现货 | |
25 mg | ¥ 2,380 | 现货 | |
50 mg | ¥ 3,400 | 现货 | |
100 mg | ¥ 4,730 | 现货 | |
200 mg | ¥ 6,380 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 1,050 | 现货 |
产品描述 | SRI 31215 TFA, a small molecule that acts as a triplex inhibitor of matriptase, hepsin and HGFA and mimics the activity of HAI-1/2, endogenous inhibitors of HGF activation with IC50s of 0.69 μM, 0.65 μM, 0.3 μM, |
靶点活性 | Hepsin:0.65 μM , HGFA:0.3 μM, Matriptase:0.69 μM |
体外活性 | SRI 31215 抑制成纤维细胞促进的MET激活、上皮-间充质转换以及癌细胞的迁移。它能克服HGF产生的结肠癌细胞对西妥昔单抗和吉非替尼的初级抗性,并阻止成纤维细胞介导的对表皮生长因子受体抑制剂的抗性。因此,SRI 31215 阻断癌细胞与成纤维细胞之间的信号传递,并抑制癌相关成纤维细胞的肿瘤促进活动。 |
细胞实验 | DU145 cells were cultured in 6-well tissue culture plates at a density of 1 103 cells per well.?After colonies formed (6-8 days), cells were serum-starved overnight and were then treated with recombinant HGF (10 ng/ml) or with conditioned media from 18Co fibroblasts in the presence or absence of SRI 31215 (10 μM) or the MET kinase inhibitor JNJ 38877605 (1 μM) for 24 hours.?Cells were washed with PBS and colonies were fixed and stained with 0.5% crystal violet solution in 6% glutaraldehyde. |
别名 | SRI 31215 |
分子量 | 533.6 |
分子式 | C27H34F3N5O3 |
CAS No. | 1832686-44-8 |
Smiles | OC(=O)C(F)(F)F.CC1CN(CC2CCN(Cc3ccccc3)CC2)C(=O)N(C1)c1cccc(c1)C(N)=N |
密度 | no data available |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||
溶解度信息 | DMSO: 25 mg/mL (38.6 mM) | |||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容